CIK 1496201
Long positions in SEC Section 13(f) securities (US-listed stocks, ADRs and ETFs), largest first · Δ vs 2025-Q4. A lagged quarterly snapshot (filed ≤45 days after quarter-end); excludes shorts, options, cash, and shares listed only on non-US exchanges — foreign companies held via a US listing or ADR (e.g. Alibaba, TSMC) ARE included.
As filed = each book applied at its quarter-end (what the reported book did) · As copyable = applied at its statutory 45-day filing deadline (what a 13F follower could have earned).
Computing…
Hypothetical modeled performance constructed with hindsight — not actual results, and not indicative of future results. See the Disclaimer.
| Industry group | Weight | Names |
|---|---|---|
| Pharmaceuticals & Biotechnology | 74.79% | 74 |
| Unclassified | 10.35% | 9 |
| Semiconductors & Semiconductor Equipment | 6.86% | 4 |
| Technology Hardware & Equipment | 5.44% | 2 |
| Utilities | 1.31% | 1 |
| Specialty Retail | 1.14% | 1 |
| Software | 0.11% | 1 |
| # | Ticker | Name | Sector | Weight |
|---|---|---|---|---|
| 1 | MLYS | Mineralys Therapeutics, Inc. | Health Care | 6.24% |
| 2 | TEVA | TEVA PHARMACEUTICAL INDUSTRIES LTD | Health Care | 5.89% |
| 3 | TSEM | Tower Semiconductor Ltd | Information Technology | 4.40% |
| 4 | NVMI | Nova Ltd. | Information Technology | 3.99% |
| 5 | BBIO | BridgeBio Pharma, Inc. | Health Care | 3.13% |
| 6 | BIIB | BIOGEN INC. | Health Care | 2.92% |
| 7 | RARE | Ultragenyx Pharmaceutical Inc. | Health Care | 2.92% |
| 8 | SNDX | Syndax Pharmaceuticals Inc | Health Care | 2.91% |
| 9 | COGT | Cogent Biosciences, Inc. | Health Care | 2.76% |
| 10 | SNY | Sanofi | Health Care | 2.23% |
83/92 names classified · sector 89.6% of weight · industry 89.6% · mkt cap 72.8%; unclassified names shown, never dropped.
Sector is classified on each name's CURRENT fundamentals, not point-in-time — apparent sector drift can reflect the market re-rating a holding, not a manager trade. 13F is a lagged quarterly snapshot of long positions in US-listed securities only — foreign companies held via a US listing or ADR ARE included, but shares listed only on non-US exchanges (plus shorts, options and cash) are not. Latest quarter: 89.6% of the book is sector-classified (unclassified names shown, never dropped).
Only 24% of book weight classified — the grid is NOT representative of the whole book.
Classified: 23.9% of book weight (17/89 names) · unclassified 76.1%: MLYS, , TSEM, NVMI, BBIO, RARE, SNDX, COGT, SNY, AZN +62 more. Size: cap 70/20/10 bands; style: value/growth composite on our own metrics — not Morningstar's model.
No contribution data for this period.
| # | Security | Shares | Value | Weight | Δ QoQ |
|---|---|---|---|---|---|
| 1 | MLYSMINERALYS THERAPEUTICS INC | 1,339,971 | $36M | 6.2% | ADD 198% |
| 2 | TEVATEVA PHARMACEUTICAL INDS LTD | 1,136,975 | $34M | 5.9% | HOLD |
| 3 | TSEMTOWER SEMICONDUCTOR LTD | 145,735 | $26M | 4.4% | ADD 19% |
| 4 | NVMINOVA LTD | 53,366 | $23M | 4.0% | ADD 12% |
| 5 | BBIOBRIDGEBIO PHARMA INC | 245,246 | $18M | 3.1% | ADD 128% |
| 6 | BIIBBIOGEN INC | 92,526 | $17M | 2.9% | TRIM −2% |
| 7 | RAREULTRAGENYX PHARMACEUTICAL IN | 809,333 | $17M | 2.9% | ADD 169% |
| 8 | SNDXSYNDAX PHARMACEUTICALS INC | 724,563 | $17M | 2.9% | TRIM −5% |
| 9 | COGTCOGENT BIOSCIENCES INC | 416,340 | $16M | 2.8% | ADD 10% |
| 10 | SNYSANOFI SA | 269,515 | $13M | 2.2% | ADD 13% |
| 11 | AZNASTRAZENECA PLC | 62,530 | $12M | 2.1% | NEW |
| 12 | AMICUS THERAPEUTICS INC | 603,377 | $9M | 1.5% | TRIM −8% |
| 13 | CLBTCELLEBRITE DI LTD | 631,521 | $9M | 1.5% | NEW |
| 14 | APELLIS PHARMACEUTICALS INC | 214,914 | $9M | 1.5% | TRIM −14% |
| 15 | PANWPALO ALTO NETWORKS INC | 52,800 | $8M | 1.5% | NEW |
| 16 | LLYELI LILLY & CO | 9,040 | $8M | 1.4% | HOLD |
| 17 | BCRXBIOCRYST PHARMACEUTICALS INC | 866,464 | $8M | 1.4% | ADD 3% |
| 18 | CAMTCAMTEK LTD | 53,020 | $8M | 1.4% | ADD 34% |
| 19 | BMRNBIOMARIN PHARMACEUTICAL INC | 139,900 | $8M | 1.4% | TRIM −5% |
| 20 | CLDXCELLDEX THERAPEUTICS INC NEW | 243,575 | $8M | 1.3% | HOLD |
| 21 | ORAORMAT TECHNOLOGIES INC | 68,250 | $8M | 1.3% | NEW |
| 22 | XENEXENON PHARMACEUTICALS INC | 127,000 | $7M | 1.3% | NEW |
| 23 | SOLENO THERAPEUTICS INC | 216,281 | $7M | 1.2% | ADD 59% |
| 24 | TNGXTANGO THERAPEUTICS INC | 343,563 | $7M | 1.2% | TRIM −37% |
| 25 | JNJJOHNSON & JOHNSON | 28,831 | $7M | 1.2% | TRIM −20% |
| 26 | SOLAREDGE TECHNOLOGIES INC | 4,000,000 | $7M | 1.2% | HOLD |
| 27 | IMTXIMMATICS N.V | 696,105 | $7M | 1.2% | TRIM −19% |
| 28 | TRVITREVI THERAPEUTICS INC | 574,029 | $7M | 1.2% | TRIM −4% |
| 29 | ORICORIC PHARMACEUTICALS INC | 537,628 | $7M | 1.2% | TRIM −46% |
| 30 | MAZEMAZE THERAPEUTICS INC | 227,343 | $7M | 1.2% | ADD 216% |
| 31 | GSKGSK PLC | 122,000 | $7M | 1.2% | HOLD |
| 32 | AMZNAMAZON COM INC | 31,940 | $7M | 1.1% | NEW |
| 33 | ABBVABBVIE INC | 30,256 | $7M | 1.1% | ADD 20% |
| 34 | AAOIAPPLIED OPTOELECTRONICS INC | 73,400 | $6M | 1.1% | NEW |
| 35 | ELVNENLIVEN THERAPEUTICS INC | 153,265 | $6M | 1.0% | TRIM −32% |
| 36 | MRKMERCK & CO INC | 48,600 | $6M | 1.0% | HOLD |
| 37 | VORVOR BIOPHARMA INC | 321,917 | $6M | 1.0% | TRIM −22% |
| 38 | ACADACADIA PHARM | 256,202 | $6M | 1.0% | ADD 21% |
| 39 | NVSNOVARTIS AG | 37,000 | $6M | 1.0% | HOLD |
| 40 | ELDNELEDON PHARMACEUTICALS INC | 1,772,131 | $5M | 0.9% | TRIM −17% |
| 41 | ENPHENPHASE ENERGY INC | 142,419 | $5M | 0.9% | TRIM −24% |
| 42 | RVMDREVOLUTION MEDICINES INC | 55,110 | $5M | 0.9% | ADD 5% |
| 43 | PFEPFIZER INC | 186,000 | $5M | 0.9% | ADD 116% |
| 44 | BHVNBIOHAVEN LTD | 594,000 | $5M | 0.9% | NEW |
| 45 | FBRXFORTE BIOSCIENCES INC | 184,984 | $5M | 0.8% | HOLD |
| 46 | HELPCYBIN INC | 987,090 | $5M | 0.8% | ADD 20% |
| 47 | MDGLMADRIGAL PHARMACEUTICALS INC | 9,040 | $5M | 0.8% | ADD 174% |
| 48 | SRRKSCHOLAR ROCK HLDG CORP | 94,265 | $5M | 0.8% | TRIM −40% |
| 49 | NVONOVO-NORDISK A S | 120,677 | $4M | 0.8% | ADD 4% |
| 50 | MDWDMEDIWOUND LTD | 273,192 | $4M | 0.8% | ADD 19% |
| 51 | KODKODIAK SCIENCES INC | 114,796 | $4M | 0.8% | TRIM −35% |
| 52 | ZBIOZENAS BIOPHARMA INC | 214,334 | $4M | 0.7% | NEW |
| 53 | PMNPROMIS NEUROSCIENCES INC | 325,591 | $4M | 0.7% | ADD 2658% |
| 54 | RLAYRELAY THERAPEUTICS INC | 408,436 | $4M | 0.7% | NEW |
| 55 | SVRASAVARA INC | 739,164 | $4M | 0.7% | TRIM −37% |
| 56 | WVEWAVE LIFE SCIENCES LTD | 548,272 | $4M | 0.7% | ADD 34% |
| 57 | CRVSCORVUS PHARMACEUTICALS INC | 247,961 | $4M | 0.6% | TRIM −39% |
| 58 | OVIDOVID THERAPEUTICS INC | 1,622,828 | $4M | 0.6% | NEW |
| 59 | IRONDISC MEDICINE INC | 53,538 | $3M | 0.6% | NEW |
| 60 | UPBUPSTREAM BIO INC | 358,000 | $3M | 0.6% | NEW |
| 61 | ACOGALPHA COGNITION INC | 567,616 | $3M | 0.5% | HOLD |
| 62 | PALIPALISADE BIO INC | 1,733,471 | $3M | 0.5% | ADD 842% |
| 63 | DYNDYNE THERAPEUTICS INC | 160,594 | $3M | 0.5% | TRIM −59% |
| 64 | CLYMCLIMB BIO INC | 419,247 | $3M | 0.5% | TRIM −55% |
| 65 | ZIMZIM INTEGRATED SHIPPING SERV | 105,950 | $3M | 0.5% | TRIM −22% |
| 66 | MSLESATELLOS BIOSCIENCE INC | 489,207 | $3M | 0.5% | NEW |
| 67 | SEDGSOLAREDGE TECHNOLOGIES INC | 52,836 | $3M | 0.5% | TRIM −73% |
| 68 | AMGNAMGEN INC | 7,500 | $3M | 0.5% | HOLD |
| 69 | CYTKCYTOKINETICS INC | 39,817 | $3M | 0.5% | TRIM −57% |
| 70 | GPCRSTRUCTURE THERAPEUTICS INC | 50,800 | $2M | 0.4% | ADD 24% |
| 71 | KURAKURA ONCOLOGY INC | 295,522 | $2M | 0.4% | HOLD |
| 72 | GENBGENERATE BIOMEDICINES INC | 185,000 | $2M | 0.4% | NEW |
| 73 | IBITISHARES BITCOIN TRUST ETF | 59,505 | $2M | 0.4% | ADD 98% |
| 74 | CTNMCONTINEUM THERAPEUTICS INC | 173,475 | $2M | 0.4% | HOLD |
| 75 | TENXTENAX THERAPEUTICS INC | 136,015 | $2M | 0.4% | TRIM −28% |
| 76 | PRLDPRELUDE THERAPEUTICS INC | 558,339 | $2M | 0.3% | ADD 355% |
| 77 | ASNDASCENDIS PHARMA A/S | 8,000 | $2M | 0.3% | TRIM −27% |
| 78 | VSTMVERASTEM INC | 343,678 | $2M | 0.3% | HOLD |
| 79 | VYGRVOYAGER THERAPEUTICS INC | 469,761 | $2M | 0.3% | ADD 38% |
| 80 | STTKSHATTUCK LABS INC | 280,786 | $2M | 0.3% | ADD 44% |
| 81 | EVMNEVOMMUNE INC | 78,234 | $2M | 0.3% | TRIM −53% |
| 82 | BIOABIOAGE LABS INC | 86,518 | $2M | 0.3% | TRIM −64% |
| 83 | ORGOORGANOGENESIS HLDGS INC | 550,000 | $1M | 0.2% | NEW |
| 84 | CRISCURIS INC | 1,994,937 | $1M | 0.2% | NEW |
| 85 | BMYBRISTOL-MYERS SQUIBB CO | 17,500 | $1M | 0.2% | HOLD |
| 86 | CTMXCYTOMX THERAPEUTICS INC. | 220,000 | $1M | 0.2% | NEW |
| 87 | NICENICE LTD | 5,611 | $618,669 | 0.1% | NEW |
| 88 | HOWLWEREWOLF THERAPEUTICS INC | 626,810 | $521,882 | 0.1% | HOLD |
| 89 | SKYESKYE BIOSCIENCE INC | 678,928 | $417,269 | 0.1% | ADD 42% |
| 90 | DTILPRECISION BIOSCIENCES INC | 40,000 | $220,000 | 0.0% | TRIM −90% |
| 91 | APREAPREA THERAPEUTICS INC | 270,000 | $205,983 | 0.0% | HOLD |
| 92 | FHTXFOGHORN THERAPEUTICS INC | 12,224 | $58,431 | 0.0% | NEW |
| Security | 2024-Q4 | 2025-Q1 | 2025-Q2 | 2025-Q3 | 2025-Q4 | 2026-Q1 | Latest value |
|---|---|---|---|---|---|---|---|
| MLYSMINERALYS THERAPEUTICS INC | 191K | 466K | 481K | 220K | 449K | 1.3M | $36M |
| TEVATEVA PHARMACEUTICAL INDS LTD | 1.6M | 1.6M | 1.6M | 1.5M | 1.1M | 1.1M | $34M |
| TSEMTOWER SEMICONDUCTOR LTD | 166K | 62K | 265K | 312K | 123K | 146K | $26M |
| NVMINOVA LTD | 68K | 91K | 76K | 44K | 48K | 53K | $23M |
| BBIOBRIDGEBIO PHARMA INC | 905K | 367K | 87K | 41K | 108K | 245K | $18M |
| BIIBBIOGEN INC | 23K | 23K | 83K | 83K | 95K | 93K | $17M |
| RAREULTRAGENYX PHARMACEUTICAL IN | 229K | 267K | 100K | 353K | 301K | 809K | $17M |
| SNDXSYNDAX PHARMACEUTICALS INC | 1.4M | 1.7M | 1.6M | 388K | 763K | 725K | $17M |
| COGTCOGENT BIOSCIENCES INC | — | 335K | 144K | 99K | 379K | 416K | $16M |
| SNYSANOFI SA | 385K | 305K | 220K | 220K | 240K | 270K | $13M |
| AZNASTRAZENECA PLC | — | — | — | — | — | 63K | $12M |
| AMICUS THERAPEUTICS INC | — | — | 991K | 991K | 658K | 603K | $9M |
| CLBTCELLEBRITE DI LTD | — | — | — | 299K | — | 632K | $9M |
| APELLIS PHARMACEUTICALS INC | 206K | 181K | 114K | 64K | 251K | 215K | $9M |
| PANWPALO ALTO NETWORKS INC | — | — | 13K | — | — | 53K | $8M |
Shares reported each quarter by the largest current holdings. Green = added vs the prior filing of that name, red = trimmed, grey = roughly held; a dash is a quarter with no 13F on file (a gap is skipped, not read as an exit). 13F is filed up to 45 days after quarter-end. Up to 40 quarters (10 years) available — use the selector above.
Where this firm's principals came from and which firms its alumni went on to found.
